Literature DB >> 24041672

Different effects of three interferons L on Toll-like receptor-related gene expression in HepG2 cells.

Tatsuo Kanda1, Xia Jiang, Shingo Nakamoto, Masato Nakamura, Tatsuo Miyamura, Shuang Wu, Osamu Yokosuka.   

Abstract

IFNL1 (IL29), IFNL2 (IL28A) and IFNL3 (IL28B) might play important roles in anti-viral defense. IFNL3 genotypes have been shown to be associated with hepatitis C spontaneous and treatment-induced viral clearance. The effects of IFNL1, IFNL2 and IFNL3 on innate immunity including Toll-like receptor (TLR)-related pathway in human hepatocytes were examined. After G418 screening, we established the human hepatoma stable cell lines HepG2-IL28A, HepG2-IL28B, and HepG2-IL29, expressing IFNL2, IFNL3, and IFNL1 in conditioned medium, respectively, and a control cell line, HepG2-pcDNA3.1. We performed real-time RT-PCR to investigate 84 Toll-like receptor-related gene expressions in triplicate and, using ddCt methods, compared these gene expressions in each cell line. IFNL2, IFNL3 and IFNL1 were respectively detected by ELISA in HepG2-IL28A, HepG2-IL28B and HepG2-IL29. Compared to HepG2-pcDNA3.1 cells, 17 (20.2%), 11 (13.0%) and 16 genes (19.0%) were up-regulated 1.5-fold or more (p<0.05); 10 (11.9%), 2 (2.3%) and 10 genes (11.9%) were 1.5-fold or more down-regulated (p<0.05) in HepG2-IL28A, HepG2-IL28B and HepG2-IL29, respectively. EIF2AK2 and SARM1 were up-regulated among all cells. Of interest, TLR3, TLR4 and related molecules CXCL10 (IP10), IL6, EIF2K2, IFNB1, and IRF1, important genes in the progression of HCV-related pathogenesis and antiviral activities against HCV, in HepG2-IL28B, presented different profiles from those of HepG2-IL28A and HepG2-IL29. IFNL3 induces interferon-stimulated genes (ISGs) that are reportedly associated with the progression of HCV-related pathogenesis and antiviral activities against HCV. IFNL is a powerful modulator of innate immune response and it is supposed that the 3 IFNLs may play different roles in the antiviral activity against HBV and HCV.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatitis C virus; IL28B; ISGs; Innate immune response; Toll-like receptor

Mesh:

Substances:

Year:  2013        PMID: 24041672     DOI: 10.1016/j.cyto.2013.08.010

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?

Authors:  Tatsuo Kanda; Shingo Nakamoto; Osamu Yokosuka
Journal:  World J Virol       Date:  2015-08-12

Review 2.  Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions.

Authors:  Sreedhar Chinnaswamy
Journal:  J Interferon Cytokine Res       Date:  2014-02-20       Impact factor: 2.607

3.  IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase.

Authors:  Tatsuo Miyamura; Tatsuo Kanda; Masato Nakamura; Xia Jiang; Shuang Wu; Shingo Nakamoto; Shigeru Mikami; Nobuo Takada; Fumio Imazeki; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2013-11-27

4.  IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens.

Authors:  Tatsuo Miyamura; Tatsuo Kanda; Shingo Nakamoto; Makoto Arai; Masato Nakamura; Shuang Wu; Xia Jiang; Reina Sasaki; Yuki Haga; Shin Yasui; Yoshihiko Ooka; Tetsuhiro Chiba; Fumio Imazeki; Shigeru Mikami; Osamu Yokosuka
Journal:  Int J Hepatol       Date:  2014-12-08

Review 5.  Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies.

Authors:  Laura A Novotny; John Grayson Evans; Lishan Su; Haitao Guo; Eric G Meissner
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.048

6.  Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.

Authors:  Junjie Wu; Marie Jordan; David J Waxman
Journal:  BMC Cancer       Date:  2016-08-11       Impact factor: 4.430

7.  Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines.

Authors:  Reina Sasaki; Tatsuo Kanda; Mariko Fujisawa; Naoki Matsumoto; Ryota Masuzaki; Masahiro Ogawa; Shunichi Matsuoka; Kazumichi Kuroda; Mitsuhiko Moriyama
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.